Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A1EWVY8
Tue, 27.05.2025
Formycon AG
Press Release // May 27, 2025
Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar, in Canada
FYB202/Otulfi™ is now commercially available in Canada in both subcutaneous and intravenous formulations
Launch expands market presence beyond the U.S. and Europe, offering broader treatment [ … ]
Mon, 19.05.2025
Formycon AG
Press Release // May 19, 2025
Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce today that the U.S. Food and Drug Administration (FDA) designated F [ … ]
Mon, 12.05.2025
Formycon AG
Press Release // May 12, 2025
Formycon reports strong operational performance and financial results for first quarter of 2025
Strong operational start to the year with market approvals for FYB203 (Aflibercept) in Europe and the United Kingdom as well as new commercialization partnerships with Teva and Lotus
Encouraging market launch of FYB202/Ot [ … ]
Wed, 07.05.2025
Formycon AG
Presse Release // May 7, 2025Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its results for the first quarter of 2025 on May 12, 2025. The Management [ … ]
Thu, 27.03.2025
Formycon AG
Press Release // March 27, 2025
Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
Group revenue exceeds forecast with €69.7 million (guidance: €55.0 million to €65.0 million)
Group EBITDA at €-13.7 million also better than expected (guidance: €-25.0 mil [ … ]
Mon, 24.03.2025
Formycon AG
Press Release // March 24, 2025
Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today announced details of the conference call for the release of the fisca [ … ]
Mon, 03.03.2025
Formycon AG
Press Release // March 3, 2025
FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union
FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous formulations in the United States and the European Union
Patient transition to Otulfi® supported by comparable effic [ … ]
Tue, 25.02.2025
Formycon AG
Press Release // February 25, 2025
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases
UK market authorization [ … ]
Thu, 20.02.2025
Formycon AG
Press Release // February 20, 2025
Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) will present an overview of the comparative data of the ustekinumab biosimilar FYB202 at this year's Congress of the European Croh [ … ]
Mon, 17.02.2025
Formycon AG
Press Release // February 17, 2025
Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
Formycon continues FYB206 development without Phase III trial and thus takes pioneering role among pembrolizumab biosimilar developers; investment savings expected to amount to a high double-digit millio [ … ]